Drugs / CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06793241 | Jan 2025 → Jan 2028 expected | B-cell acute lymphoblastic leukemia | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06793241 ↗ |
| Modality | Cell therapy | “CD19 CAR-T Cells therapy” NCT06793241 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06793241 ↗ |
| Target | CD19 | “CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells” NCT06793241 ↗ |